What does CONTIPHARMA do?

CONTIPHARMA is a wholesaler in Seraing. Public Limited, started on 9 September 1999, 1 establishment.

What is the address of CONTIPHARMA?

The registered office of CONTIPHARMA is located at Rue de l'Environnement 22, 4100 Seraing.

Is CONTIPHARMA still active?

Yes. According to the CBE (30 October 2026) CONTIPHARMA is active, legal situation “Normale toestand”, started on 9 September 1999.

Is CONTIPHARMA registered on Peppol?

Yes, CONTIPHARMA is registered on the Peppol network with ID 0208:0466820220.

What is the enterprise number of CONTIPHARMA?

The enterprise number of CONTIPHARMA is BE0466820220.

When was CONTIPHARMA founded?

CONTIPHARMA was founded on 9 September 1999.

Who are the directors of CONTIPHARMA?

According to the 2025 annual accounts, the directors of CONTIPHARMA are: Rachel Delhez, Bernard Delhez.

Is CONTIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 September 1999; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CONTIPHARMA make in 2025?

CONTIPHARMA posted a profit after taxes of € 1,067,762 in financial year 2025.

What is the revenue of CONTIPHARMA?

As a small company, CONTIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,677,653.

How much does an employee at CONTIPHARMA earn?

The average wage cost per full-time employee at CONTIPHARMA was € 80,800 in 2025: staff costs of € 105,060 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CONTIPHARMA have?

According to the 2025 annual accounts, CONTIPHARMA has 1.3 full-time equivalents (FTE).

Does CONTIPHARMA have a website?

Yes, CONTIPHARMA has a website at contipharma-protect.com.

CONTIPHARMA (Public Limited) - Seraing - BE0466820220

Dossier CONTIPHARMA, printed on 30 October 2026 from databakkes.be/en/0466820220/contipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Board fully replaced NBB

No director from three years ago is still active according to annual account 2025.

Financials

Financial year 2025

CONTIPHARMA from Seraing, company number BE0466820220, closed financial year 2025 with a result of € 1.1 million after tax. For that financial year CONTIPHARMA recorded a gross margin of € 2.7 million and equity of € 3.2 million. Compared with financial year 2024, the result moved from € -151,785 to € 1.1 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 14, 2026.

What it is worth Growing

€ 3.2 million

▲ 49% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 1.1 million

▲ still € 151,785 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 705,529

▲ 15% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.3 million.

People and assets in 2025

Full-time equivalents

1.3

▲ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 105,060

▲ 33% vs 2024

€ 80,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 111,908

▲ 182% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 102,224

▼ 93% vs 2024

€ 23,430 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 983,055

▲ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 26,193

▲ 160% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -38,844 Gross margin 2022: € -38,844 First fiscal year in the series	€ -47,295 Gross margin 2023: € -47,295 ▼ € 8,450 vs 2022 (€ -38,844) Unfavourable step	€ -95,623 Gross margin 2024: € -95,623 ▼ € 48,329 vs 2023 (€ -47,295) Unfavourable step	€ 2,677,653 Gross margin 2025: € 2,677,653 ▲ € 2.8 million vs 2024 (€ -95,623) Favourable step	▲ € 2.8 million
Profit after taxes	€ -130,928 Profit after taxes 2022: € -130,928 First fiscal year in the series	€ -113,781 Profit after taxes 2023: € -113,781 ▲ € 17,147 vs 2022 (€ -130,928) Favourable step	€ -151,785 Profit after taxes 2024: € -151,785 ▼ € 38,004 vs 2023 (€ -113,781) Unfavourable step	€ 1,067,762 Profit after taxes 2025: € 1,067,762 ▲ € 1.2 million vs 2024 (€ -151,785) Favourable step	▲ € 1.2 million
Equity	€ 2,432,348 Equity 2022: € 2,432,348 First fiscal year in the series	€ 2,318,568 Equity 2023: € 2,318,568 ▼ 5% vs 2022 (€ 2,432,348) Unfavourable step	€ 2,166,783 Equity 2024: € 2,166,783 ▼ 7% vs 2023 (€ 2,318,568) Unfavourable step	€ 3,234,545 Equity 2025: € 3,234,545 ▲ 49% vs 2024 (€ 2,166,783) Favourable step	▲ 49%
Total debts	€ 2,879,708 Total debts 2022: € 2,879,708 First fiscal year in the series	€ 3,227,747 Total debts 2023: € 3,227,747 ▲ 12% vs 2022 (€ 2,879,708) Unfavourable step	€ 5,015,613 Total debts 2024: € 5,015,613 ▲ 55% vs 2023 (€ 3,227,747) Unfavourable step	€ 3,977,978 Total debts 2025: € 3,977,978 ▼ 21% vs 2024 (€ 5,015,613) Favourable step	▼ 21%
Cash	€ 40,747 Cash 2022: € 40,747 First fiscal year in the series	€ 66,835 Cash 2023: € 66,835 ▲ 64% vs 2022 (€ 40,747) Favourable step	€ 611,264 Cash 2024: € 611,264 ▲ € 544,429 vs 2023 (€ 66,835) Favourable step	€ 705,529 Cash 2025: € 705,529 ▲ 15% vs 2024 (€ 611,264) Favourable step	▲ 15%
Retained profit	€ 524,438 Retained profit 2022: € 524,438 First fiscal year in the series	€ 410,658 Retained profit 2023: € 410,658 ▼ 22% vs 2022 (€ 524,438) Unfavourable step	€ 258,873 Retained profit 2024: € 258,873 ▼ 37% vs 2023 (€ 410,658) Unfavourable step	€ 1,326,635 Retained profit 2025: € 1,326,635 ▲ € 1.1 million vs 2024 (€ 258,873) Favourable step	▲ € 1.1 million
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 197,743 Bank debt 2023: € 197,743 Unchanged (€ 0) Unfavourable step	€ 1,420,748 Bank debt 2024: € 1,420,748 ▲ € 1.2 million vs 2023 (€ 197,743) Unfavourable step	€ 102,224 Bank debt 2025: € 102,224 ▼ 93% vs 2024 (€ 1,420,748) Favourable step	▼ 93%
Balance sheet total	€ 5,312,056 Balance sheet total 2022: € 5,312,056 First fiscal year in the series	€ 5,546,315 Balance sheet total 2023: € 5,546,315 ▲ 4% vs 2022 (€ 5,312,056) Unchanged	€ 7,182,396 Balance sheet total 2024: € 7,182,396 ▲ 29% vs 2023 (€ 5,546,315) Unchanged	€ 7,212,523 Balance sheet total 2025: € 7,212,523 Unchanged (€ 7,182,396) Unchanged
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1 Employees (FTE) 2023: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1.3 Employees (FTE) 2025: 1.3 ▲ 0.3 vs 2024 (1) Unchanged	▲ 0.3

Key figures of CONTIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CONTIPHARMA?

What happened at CONTIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Bernard Delhez stepped down as director. NBB
Oct 14, 2026 New annual accounts for financial year 2025: profit of € 1.1 million. filed late Source: NBB ↗
2021 Bernard Delhez became a director. NBB
Sep 14, 1999 New establishment in Seraing. KBO
Sep 9, 1999 Start of the company according to the CBE. KBO

In short

From € 130,928 loss in 2022 to € 1.1 million profit in 2025.

Paid € 8,947 in corporate taxes since 2022.

Best year ever: 2025, with € 1.1 million profit.

On average € 2.1 million of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Rachel Delhez

CONTIPHARMA

BEDELCO 100%

BEREMAT 51%

Behind CONTIPHARMA is Rachel Delhez. It owns 100% of BEDELCO and 51% of BEREMAT itself.

Directors

According to the 2025 annual accounts

Rachel Delhez

Director

Bernard Delhez

Director

Also active at: GEDELFIN, BEDELCO

since 2021 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de l'Environnement 22

4100 Seraing

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

BEDELCO same network

€ 844,259 revenue · 2025

Lynx Capital

€ -1,887 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS contipharma-protect.com

About

Technologies

ApacheAvadaContact Form 7Font AwesomeGoogle AnalyticsGoogle FontsGravity FormsPHPW3 Total CacheWPMLWooCommerceWordPressYoast SEOYouTube EmbedjQuerylazysizes

Hosting & Email

Email provider

Self-hosted

Hosting

CELESTE-AS CELESTE - Internet services provider, FR

Domain

contipharma-protect.com

Registered

2021-06-15

Registrar

PHPNET France DBA Nuxit

Expires

2026-06-15

Website info

HTTPS Ja

Languages EN, FR

Features

Webshop

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ Load balancing

Details

Company number

0466.820.220

VAT number

BE 0466.820.220

Registered office

Rue de l'Environnement 22, 4100 Seraing

Names & denominations

CONTIPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

9 September 1999

Peppol

Active · Active since 3 Dec 2025

Contact

contipharma-protect.com

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Activiteiten van holdings

Detailhandel in farmaceutische producten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

CONTIPHARMA

Warning lights

Financials

What happened to CONTIPHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Domain

Website info

Features

Security

Network

Details

Frequently asked questions